PURE Bioscience, Inc.
PURE · OTC
7/31/2025 | 7/31/2024 | 7/31/2023 | 7/31/2022 | |
|---|---|---|---|---|
| Market Cap | $10,045 | $8,926 | $9,469 | $17,501 |
| - Cash | $334,000 | $349 | $1,095 | $3,391 |
| + Debt | $5,236,000 | $2,949 | $1,021 | $0 |
| Enterprise Value | $4,912,045 | $11,526 | $9,395 | $14,110 |
| Revenue | $2,202,000 | $1,963 | $1,877 | $1,853 |
| % Growth | 112,075.2% | 4.6% | 1.3% | – |
| Gross Profit | $1,303,000 | $1,152 | $971 | $1,000 |
| % Margin | 59.2% | 58.7% | 51.7% | 54% |
| EBITDA | -$2,098 | -$3,047 | -$3,830 | -$3,272 |
| % Margin | -0.1% | -155.2% | -204% | -176.6% |
| Net Income | -$2,399 | -$3,350 | -$3,961 | -$3,497 |
| % Margin | -0.1% | -170.7% | -211% | -188.7% |
| EPS Diluted | -0.021 | -0.03 | -0.036 | -0.039 |
| % Growth | 28.4% | 16% | 9.6% | – |
| Operating Cash Flow | -$2,015,000 | -$2,531 | -$3,278 | -$2,418 |
| Capital Expenditures | $0 | $0 | -$33 | -$81 |
| Free Cash Flow | -$2,015,000 | -$2,531 | -$3,311 | -$2,499 |